EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma

Kazuhiro Kitajima, Kozo Kuribayashi, Toshiyuki Minami, Hiroyuki Yokoyama, Akifumi Nakamura, Masaki Hashimoto, Takashi Kijima, Seiki Hasegawa, Hayato Kaida, Koichiro Yamakado

Oncotarget · 2024

DOI: 10.18632/oncotarget.28594 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Oncotarget, 2024. Verfasst von Kazuhiro Kitajima und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan. Hauptthemen laut MEDLINE: Ipilimumab, Nivolumab, Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Results for malignant pleural mesothelioma (MPM) patients following first-line treatment with nivolumab plus ipilimumab obtained with immunotherapy-modified PERCIST (imPERCIST), shown by [18F]fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and modified RECIST (mRECIST), shown by CT, were compared for response evaluation and prognosis prediction. RESULTS: imPERCIST indicated nine progressive metabolic disease (PMD), eight stable metabolic disease (SMD), four partial metabolic response (PMR), and five complete metabolic response (CMR) cases. mRECIST showed nine with progressive disease (PD), nine stable disease (SD), seven partial response (PR), and one complete response (CR). Although high concordance was noted (κ = 0.827), imPERCIST correctly judged a greater percentage with CMR (15.4%). Following a median 10.0 months, 15 patients showed progression and eight died from MPM. With both, progression-free survival (PFS) and overall survival (OS) were significantly longer in patients without progression (CMR/PMR/SMD, CR/PR/SD, respectively) as compared to PMD/PD patients (imPERCIST p < 0.0001 and p = 0.015, respectively; mRECIST p < 0.0001 and p = 0.015, respectively). METHODS: Twenty-six patients (23 males, 3 females; median 73.5 years) with histologically proven MPM and no curative surgery received nivolumab plus ipilimumab combination therapy. FDG-PET/CT and diagnostic CT scanning at the baseline, and after 2-4 cycles (2 in three, 3 in 17, 4 in six patients) were performed. Therapeutic response findings evaluated using imPERCIST and mRECIST were compared. PFS and OS analyses were done using log-rank and Cox methods. CONCLUSION: For unresectable MPM patient examinations, FDG-PET and CT provide accurate findings for evaluating tumor response and also prognosis prediction following first-line nivolumab plus ipilimumab immunotherapy (approximately three cycles).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IpilimumabNivolumabFluorodeoxyglucose F18Positron Emission Tomography Computed TomographyAntineoplastic Combined Chemotherapy ProtocolsPleural NeoplasmsMesothelioma, MalignantMesotheliomaLung NeoplasmsHumansMaleFemaleAgedMiddle AgedPrognosisAged, 80 and overTomography, X-Ray ComputedTreatment Outcome

Stichwörter der Autor:innen

FDG (fluorodeoxyglucose)PET-CT (positron emission tomography-computed tomography)immunotherapyimmunotherapy-modified PERCIST (positron emission tomography response criteria…mesothelioma

Substanzen

IpilimumabNivolumabFluorodeoxyglucose F18

Autor:innen und Institutionen

  • Department of Radiology, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Department of Thoracic Surgery, Hyogo Medical University, Nishinomiya, Hyogo, Japan.
  • Department of Radiology, Kindai University Faculty of Medicine, Osaka, Japan.

Zitieren

APA

Kitajima, K., Kuribayashi, K., Minami, T., Yokoyama, H., Nakamura, A., Hashimoto, M., Kijima, T., Hasegawa, S., Kaida, H., & Yamakado, K. (2024). Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Oncotarget. https://doi.org/10.18632/oncotarget.28594

Vancouver

Kitajima K, Kuribayashi K, Minami T, Yokoyama H, Nakamura A, Hashimoto M, et al. Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma. Oncotarget. 2024. doi:10.18632/oncotarget.28594

BibTeX
@article{Kitajima2024,
  author = {Kitajima, Kazuhiro and Kuribayashi, Kozo and Minami, Toshiyuki and Yokoyama, Hiroyuki and Nakamura, Akifumi and Hashimoto, Masaki and Kijima, Takashi and Hasegawa, Seiki and Kaida, Hayato and Yamakado, Koichiro},
  title = {Comparison of FDG-PET/CT and CT for evaluation of tumor response to nivolumab plus ipilimumab combination therapy and prognosis prediction in patients with unresectable malignant pleural mesothelioma},
  journal = {Oncotarget},
  year = {2024},
  doi = {10.18632/oncotarget.28594}
}
Kostenlos starten →